Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Sema G. Quadir

2 papers in the library · 17 citations · publishing 2022-2024

Papers

Increased reactivity of the paraventricular nucleus of the hypothalamus and decreased threat responding in male rats following psilocin administration.

Nature Communications June 22, 2024 Devin P. Effinger, Jessica L Hoffman, Sarah E Mott et al. 15 citations

Psilocin, the psychoactive metabolite of psilocybin, increases activity in the paraventricular nucleus of the hypothalamus (PVN) in rats, a brain region central to stress response, autonomic function, and social behavior. In male rats, psilocin heightened PVN reactivity to an aversive air-puff stimulus, driven by active threat responders, while females showed no such increase. This effect was temporary, with reactivity returning to baseline 2 and 7 days after injection. Prior psilocin did not alter PVN reactivity during acute restraint stress. The findings identify the PVN as a key site of psychedelic action with implications for threat-related behavior.

Sex-Specific Effects of Psychedelic Drug Exposure on Central Amygdala Reactivity and Behavioral Responding

bioRxiv (Cold Spring Harbor Laboratory) April 29, 2022 Devin P. Effinger, Sema G. Quadir, M. C. Ramage et al. 2 citations preprint

A single dose of psilocin, the active metabolite of psilocybin, produces sex-specific, time-dependent, and lasting changes in central amygdala (CeA) activity and reactivity to an aversive air-puff stimulus in mice. Psilocin acutely increased CeA activity in both sexes and increased stimulus-specific CeA reactivity in females but not males. In males, psilocin caused time-dependent decreases in reactivity from 2 to 28 days after administration, while females showed no such decrease. Behavioral threat responses also changed in a sex-dependent manner, with no effects on exploratory behavior or locomotion. These findings suggest enduring, sex-specific alterations in CeA function underlie psilocin's therapeutic effects in affective disorders.